贝瑞基因
(000710)
| 流通市值：24.54亿 | | | 总市值：28.92亿 |
| 流通股本：3.00亿 | | | 总股本：3.54亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 279,476,530.07 | 1,151,416,785.41 | 865,605,843.9 | 560,696,060.91 |
| 营业收入 | 279,476,530.07 | 1,151,416,785.41 | 865,605,843.9 | 560,696,060.91 |
| 利息收入 | 0 | - | - | - |
| 已赚保费 | 0 | - | - | - |
| 手续费及佣金收入 | 0 | - | - | - |
| 二、营业总成本 | 247,333,978.52 | 1,203,406,910.91 | 911,575,255.95 | 601,557,960.94 |
| 营业成本 | 125,623,428.46 | 636,220,849.03 | 474,032,155.32 | 317,358,792.44 |
| 利息支出 | 0 | - | - | - |
| 手续费及佣金支出 | 0 | - | - | - |
| 退保金 | 0 | - | - | - |
| 赔付支出净额 | 0 | - | - | - |
| 提取保险合同准备金净额 | 0 | - | - | - |
| 保单红利支出 | 0 | - | - | - |
| 分保费用 | 0 | - | - | - |
| 税金及附加 | 1,945,204.81 | 8,590,058.52 | 5,917,602.32 | 3,326,148.9 |
| 销售费用 | 59,425,744.19 | 292,467,884.56 | 230,379,289.55 | 147,085,538.09 |
| 管理费用 | 37,327,902.4 | 141,580,880.88 | 118,125,614.24 | 78,854,604.87 |
| 研发费用 | 20,699,969.47 | 110,010,752.58 | 72,322,144.99 | 47,511,079.68 |
| 财务费用 | 2,311,729.19 | 14,536,485.34 | 10,798,449.53 | 7,421,796.96 |
| 其中:利息费用 | 2,956,159.56 | 16,351,690.37 | - | 8,129,258.56 |
| 其中:利息收入 | -911,726.07 | 2,635,721.34 | - | 1,122,669.2 |
| 加:公允价值变动收益 | -2,227,059.05 | -16,042,063.02 | -20,835,871.91 | -13,580,225.64 |
| 加:投资收益 | -2,803,568.59 | -45,770,465.38 | -36,623,949.88 | -28,959,382.14 |
| 净敞口套期收益 | 0 | - | - | - |
| 汇兑收益 | 0 | - | - | - |
| 资产处置收益 | 0.01 | -14,254.14 | 1,726 | - |
| 资产减值损失(新) | 0 | -181,561,391.74 | - | - |
| 信用减值损失(新) | -13,308,559.43 | -162,863,950.83 | -21,801,272 | -9,015,209.32 |
| 其他收益 | 479,634.89 | 7,498,824.75 | 3,856,380.63 | 2,214,042.11 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 14,282,999.38 | -450,743,425.86 | -121,372,399.21 | -90,202,675.02 |
| 加:营业外收入 | 177,300.7 | 2,457,783.51 | 570,905.54 | 680,737.99 |
| 减:营业外支出 | 824,508.86 | 5,139,241.12 | 1,409,384.61 | 1,241,484.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 13,635,791.22 | -453,424,883.47 | -122,210,878.28 | -90,763,421.59 |
| 减:所得税费用 | 4,216,786.36 | -28,158,872.9 | 10,921,710.59 | 3,020,505.82 |
| 六、净利润 | 9,419,004.86 | -425,266,010.57 | -133,132,588.87 | -93,783,927.41 |
| 持续经营净利润 | 0 | -425,266,010.57 | -133,132,588.87 | -93,783,927.41 |
| 终止经营净利润 | 0 | - | - | - |
| 归属于母公司股东的净利润 | 8,235,122.95 | -427,196,505.92 | -134,956,919.35 | -95,107,757.01 |
| 少数股东损益 | 1,183,881.91 | 1,930,495.35 | 1,824,330.48 | 1,323,829.6 |
| (一)基本每股收益 | 0.02 | -1.21 | -0.38 | -0.27 |
| (二)稀释每股收益 | 0.02 | -1.21 | -0.38 | -0.27 |
| 八、其他综合收益 | 63,560.6 | 1,802,677.78 | 3,176,915.4 | 3,825,302.65 |
| 归属于母公司股东的其他综合收益 | 51,423.12 | 1,108,112.97 | 2,268,541.78 | 2,751,158.99 |
| 九、综合收益总额 | 9,482,565.46 | -423,463,332.79 | -129,955,673.47 | -89,958,624.76 |
| 归属于母公司股东的综合收益总额 | 8,286,546.07 | -426,088,392.95 | -132,688,377.57 | -92,356,598.02 |
| 归属于少数股东的综合收益总额 | 1,196,019.39 | 2,625,060.16 | 2,732,704.1 | 2,397,973.26 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-28 | 2023-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |